In a nutshell This review evaluated the effectiveness of denosumab (Prolia) on bone mineral density (BMD) and joint destruction in patients with rheumatoid arthritis (RA). The authors concluded that denosumab treatment was linked to increased BMD and reduced joint destruction in patients with RA. Some background RA is a chronic inflammatory...
Read More
In a nutshell This study investigated the effect of filgotinib (Jyseleca) on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) in patients that had active rheumatoid arthritis (RA). The study showed that filgotinib improved PROs in these patients and can be a treatment option for patients with insufficient responses to...
Read More
In a nutshell This study evaluated immune responses after two doses of SARS-CoV-2 messenger RNA (mRNA) vaccines in patients with inflammatory joint diseases including rheumatoid arthritis (RA) compared to healthy controls (HCs). The data showed that patients with inflammatory joint diseases had similar responses to mRNA vaccines after 2...
Read More
In a nutshell This study evaluated the effect of oral baricitinib (Olumiant) on the prevention of radiographic progression of joint damage over 5 years in patients with active rheumatoid arthritis (RA). The data showed that patients treated with oral baricitinib had less radiographic progression over 5 years, compared to those initially given a...
Read More
In a nutshell This study assessed the responses of patients with rheumatoid arthritis (RA) to tofacitinib (Xeljanz), tofacitinib with methotrexate (MTX; Otrexup), and adalimumab (Humira) with MTX. The data showed that some patients did not require combined therapy to achieve higher responses, however, overall, greater responses were achieved with...
Read More
In a nutshell This study looked at the risk of blood clots in patients with rheumatoid arthritis (RA) treated with biologics. It found that there was no significant increase in the risk of blood clots with biologics compared to other RA treatments. Some background Biologics are a newer type of treatment for RA. They are usually made from...
Read More
In a nutshell This study investigated the occurrence of fatigue (tiredness) in patients with early rheumatoid arthritis (RA) and identified predictors of fatigue after 24 months. The data showed that patients with early disease remission had a rapid, sustained reduction in fatigue and that low disease activity at diagnosis predicted a higher risk...
Read More
In a nutshell This study looked at the use of peficitinib (Smyraf) for the treatment of rheumatoid arthritis (RA) from the perspective of patients and their doctors. It found that peficitinib improved symptoms of RA and led to increased ability to work and carry out daily activities compared to placebo. Some background RA is a chronic...
Read More
In a nutshell This study explored the risk factors for fragility fractures in patients with rheumatoid arthritis (RA). The authors concluded that aging, disease-related factors, and previous fracture history are important risk factors for fragility fractures in these patients. Some background RA is a chronic, systemic inflammatory disease that affects...
Read More
In a nutshell This study investigated the relationships among depression and anxiety, diet, and disease activity or physical function in patients with rheumatoid arthritis (RA). The data showed that there was a relationship between depression and lower fish intake frequency in these patients. Some background RA is a chronic inflammatory...
Read More
In a nutshell This study looked at the safety and effectiveness of olokizumab (Artlegia) as an add-on to methotrexate (Otrexup) treatment in rheumatoid arthritis. It found the olokizumab was associated with significant improvements in RA symptoms and physical function. Some background Rheumatoid arthritis (RA) is a condition affecting...
Read More
In a nutshell This study compared the effectiveness and safety of tofacitinib (Xeljanz) and baricitinib (Olumiant) in patients with rheumatoid arthritis in a real-world setting. The data showed that tofacitinib and baricitinib had similar effectiveness and safety but clinical responses may depend on previous use of anti-rheumatic drugs. Some...
Read More
